Biogen’s controversial Alzheimer’s drug generates $2 million in first few weeks after approval

Biogen’s Alzheimer’s drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug. Biogen upped its revenue guidance for the year, saying it now expects total sales of $10.65 billion to $10.85 billion… Continue reading Biogen’s controversial Alzheimer’s drug generates $2 million in first few weeks after approval